Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575585 | 1.00 | TP53 (0.48) | TP53TDP1TSHRMEN1KMT2A | |
| SCHEMBL5623197 | 0.88 | TP53 (0.42) | TP53TDP1TSHRMEN1KMT2A | |
| SCHEMBL7452828 | 0.84 | TP53 (0.39) | TP53TDP1TSHRMEN1KMT2A | |
| SCHEMBL29677328 | 0.84 | TP53 (0.39) | TP53TDP1TSHRMEN1KMT2A | |
| SCHEMBL29389309 | 0.84 | KMT2A (0.58) | TP53TDP1TSHRMEN1KMT2A | |
| SCHEMBL28498569 | 0.83 | TP53 (0.38) | TP53TDP1TSHRMEN1KMT2A | |
| SCHEMBL28499171 | 0.83 | TP53 (0.38) | TP53TDP1TSHRMEN1KMT2A | |
| SCHEMBL6988942 | 0.81 | TP53 (0.37) | TP53TDP1TSHRMEN1KMT2A | |
| SCHEMBL3539649 | 0.80 | TP53 (0.32) | TP53TDP1TSHR | |
| SCHEMBL21906271 | 0.79 | TSHR (0.46) | TP53TDP1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20170210768-A1 | Novel Chiral Aziridine Phosphoramidate Compounds | CHEMAPOTHECA, LLC | 2017-07-27 | — | — | US | disclosed |
| US-9657041-B2 | Chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity >99% | CHEMAPOTHECA, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160207945-A1 | Novel chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity >99% | CHEMAPOTHECA, LLC | 2016-07-21 | — | — | US | disclosed |
| US-9278904-B2 | Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds | CHEMAPOTHECA, LLC (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150183716-A1 | Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds | CHEMAPOTHECA, LLC (US) | 2015-07-02 | — | — | US | disclosed |
| CN-102336738-B | Synthesis method of 2-thiopheneethamine | QIU YIBIN | 2014-04-16 | — | — | CN | disclosed |
| US-5593659-A | IN THE FORM OF PHYSIOLOGICALLY ACCEPTABLE SALTS; MEDICAL DIAGNOSIS; WATER SOLUBLE, NONTOXIC | CONCAT, LTD. (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0513000-B1 | MRI IMAGE ENHANCEMENT OF BONE AND RELATED TISSUE USING COMPLEXES OF PARAMAGNETIC CATIONS AND POLYPHOSPHONATE LIGANDS | CONCAT LTD (US) | 1996-07-31 | — | — | EP | disclosed |
| US-5380515-A | CONTRAST | CONCAT, LTD. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5236695-A | Medical diagnosis | CONCAT, LTD. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0513000-A1 | MRI IMAGE ENHANCEMENT OF BONE AND RELATED TISSUE USING COMPLEXES OF PARAMAGNETIC CATIONS AND POLYPHOSPHONATE LIGANDS. | CONCAT LTD (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0513000-A4 | MRI IMAGE ENHANCEMENT OF BONE AND RELATED TISSUE USING COMPLEXES OF PARAMAGNETIC CATIONS AND POLYPHOSPHONATE LIGANDS. | CONCAT LTD (US) | 1992-09-01 | — | — | EP | disclosed |
| WO-1991007911-A1 | MRI IMAGE ENHANCEMENT OF BONE AND RELATED TISSUE USING COMPLEXES OF PARAMAGNETIC CATIONS AND POLYPHOSPHONATE LIGANDS | CONCAT LTD. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | TP53 4534/4885TDP1 1222/4885TSHR 1602/4885 |
| US-20160207945-A1 | Novel chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity >99% | DDT, ABL1, SLC6A3 | TP53 4666/4885TDP1 1155/4885TSHR 1331/4885 |
| US-20170210768-A1 | Novel Chiral Aziridine Phosphoramidate Compounds | DDT, SLC6A3, PNMT | TP53 4607/4885TDP1 1286/4885TSHR 2009/4885 |
| US-20150183716-A1 | Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds | DDT, SLC6A3, TYR | TP53 4753/4885TDP1 1471/4885TSHR 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.